Literature DB >> 28654630

PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.

Russell Pokroy1, Michael Mimouni2, Edward Barayev3, Fani Segev3, Noa Geffen3, Arie Y Nemet3, Ori Segal.   

Abstract

PURPOSE: To study the correlation between subretinal hyperreflective material (SHRM) seen on spectral domain optical coherence tomography at baseline and visual outcomes after intravitreal bevacizumab injection in neovascular age-related macular degeneration.
METHODS: Consecutive patient charts with treatment-naive center-involved neovascular age-related macular degeneration treated with 3 monthly intravitreal bevacizumab's, continued as needed, from 2011 to 2014 were reviewed. Baseline spectral domain optical coherence tomography SHRM parameters (height, width, area, reflectivity, border definition, and homogeneity) and established optical coherence tomography biomarkers of neovascular activity (intraretinal fluid, subretinal fluid, retinal volume, central retinal thickness, and pigment epithelial detachment presence) were collected. These baseline parameters were correlated with visual acuity at baseline, 3 and 12 months.
RESULTS: Seventy-three eyes of 73 patients, 47 (64.4%) having central SHRM at baseline, were studied. Mean age was 79.2 ± 8.9 years. Mean best-corrected visual acuity was 0.70 ± 0.57 logarithm of the minimum angle of resolution (20/100), 0.73 ± 0.55 (20/107), and 0.76 ± 0.63 (20/115) at baseline, 3 and 12 months, respectively. Baseline parameters with a significant predictive value of 12-month visual acuity by univariate analysis were presence of intraretinal fluid, presence of SHRM, highly reflective SHRM, well-defined SHRM borders, and thick SHRM. These parameters, with the exception of high reflectivity, were significant on multivariate regression analysis. The most predictive baseline parameter was well-defined SHRM borders.
CONCLUSION: This study supports the use of SHRM as a prognostic biomarker when interpreting optical coherence tomography in neovascular age-related macular degeneration. Baseline parameters predicting poorer vision 1 year after intravitreal bevacizumab treatment were as follows: presence of central SHRM, well-defined SHRM borders, intraretinal fluid, and thicker SHRM.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28654630     DOI: 10.1097/IAE.0000000000001748

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  10 in total

1.  The identification of activity of choroidal neovascularization complicating angioid streaks.

Authors:  Alessandro Marchese; Chiara Giuffrè; Maria Vittoria Cicinelli; Alessandro Arrigo; Francesco Bandello; Maurizio Battaglia Parodi
Journal:  Eye (Lond)       Date:  2021-05-10       Impact factor: 4.456

2.  Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Authors:  Ahmed M Hagag; Shruti Chandra; Hagar Khalid; Ali Lamin; Pearse A Keane; Andrew J Lotery; Sobha Sivaprasad
Journal:  J Clin Med       Date:  2020-06-21       Impact factor: 4.241

3.  Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial.

Authors:  Praveen J Patel; Hari Jayaram; Maria Eleftheriadou; Clara Vazquez-Alfageme; Niaz Islam; Gary S Rubin; Bishwanath Pal; Peter K Addison; Robin Hamilton; Simona Degli Esposti
Journal:  Ophthalmol Ther       Date:  2020-06-18

4.  Subretinal hyperreflective material in central serous chorioretinopathy.

Authors:  Niroj K Sahoo; Vishal Govindhari; Rumneek Bedi; Abhilash Goud; Rishi Singh; Lihteh Wu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

Review 5.  Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Authors:  Laurent Kodjikian; Mariacristina Parravano; Andreas Clemens; Rosa Dolz-Marco; Frank G Holz; Marion R Munk; Massimo Nicolò; Federico Ricci; Rufino Silva; S James Talks; Rohini Kumar Verma; Javier Zarranz-Ventura; Sandrine A Zweifel
Journal:  Eye (Lond)       Date:  2021-04-01       Impact factor: 3.775

6.  Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment.

Authors:  Alice Brandli; Fay L Khong; Roy C K Kong; Darren J Kelly; Erica L Fletcher
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

7.  IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.

Authors:  Varun Chaudhary; Frédéric Matonti; Javier Zarranz-Ventura; Michael W Stewart
Journal:  Retina       Date:  2022-04-01       Impact factor: 4.256

Review 8.  OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review.

Authors:  Cristian Metrangolo; Simone Donati; Marco Mazzola; Liviana Fontanel; Walter Messina; Giulia D'alterio; Marisa Rubino; Paolo Radice; Elias Premi; Claudio Azzolini
Journal:  J Ophthalmol       Date:  2021-07-17       Impact factor: 1.909

Review 9.  Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.

Authors:  Daniele Veritti; Valentina Sarao; Valentina Soppelsa; Carla Danese; Jay Chhablani; Paolo Lanzetta
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

10.  Validation and Clinical Applicability of Whole-Volume Automated Segmentation of Optical Coherence Tomography in Retinal Disease Using Deep Learning.

Authors:  Marc Wilson; Reena Chopra; Megan Z Wilson; Charlotte Cooper; Patricia MacWilliams; Yun Liu; Ellery Wulczyn; Daniela Florea; Cían O Hughes; Alan Karthikesalingam; Hagar Khalid; Sandra Vermeirsch; Luke Nicholson; Pearse A Keane; Konstantinos Balaskas; Christopher J Kelly
Journal:  JAMA Ophthalmol       Date:  2021-09-01       Impact factor: 7.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.